- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03211793
Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis (MANUS)
Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis: the MANUS Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The MANUS Trial is a randomized double-blind, placebo-controlled clinical trial. Patients with systemic sclerosis (SSc) and digital ischemia with intractable ischemic digital ulcers refractory to conventional treatments are eligible to participate.
20 participants will be randomised (1:1) to undergo intramuscular injection (8 sites) of allogeneic bone marrow derived mesenchymal stromal cells (BM-MSC) (45-50*10^6) or placebo in the most affected limb.
Main study parameters/endpoints: The primary outcome is the toxicity of the treatment at 12 weeks after MSC administration, defined as
- Local toxicity, including signs of local inflammation (swelling, warmth, impairment of function), worsening of ulcers or new ulcers or hematomas after MSC administration
- Other adverse events, graded according to the Common Terminology Criteria for Adverse Events version 4.0, expressed as maximum grade toxicity per organ system.
Secondary outcome measures are: number of serious adverse events, pain and disability parameters; healing, time to healing and reduction of new ischemic digital ulcers; modified Rodnan skin score; Scleroderma Health Assessment Questionnaire (S-HAQ) including visual analogue scales (VAS) for scleroderma-specific symptoms; Quality-of-life (SF-36, EuroQol (EQ-5D); Cochin hand function score. We will also evaluate changes in capillary morphology and architecture using capillaroscopy; biochemical parameters; markers for endothelial activation and injury, inflammation, oxidative stress, circulating cells including endothelial cells, hematopoietic and endothelial progenitor cells, cytokines and growth factors, immunological responses. Follow-up visits will be scheduled at 48 hours and 2, 4, 8, 12, 24 and 52 weeks post-treatment.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Femke van Rhijn, MD
- Phone Number: 0031887557329
- Email: f.c.c.brouwer-3@umcutrecht.nl
Study Locations
-
-
-
Utrecht, Netherlands, 3584 CX
- Recruiting
- Universitair Medisch Centrum Utrecht
-
Principal Investigator:
- Marianne Verhaar, MD, PhD
-
Sub-Investigator:
- Jaap van Laar, MD, PhD
-
Sub-Investigator:
- Femke van Rhijn, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Established diagnosis of SSc according to the 2013 ACR/EULAR criteria
At least one active digital ulcer (painful area, >2 mm in diameter with visible depth and loss of dermis) refractory to intravenous prostacyclins
- 'Refractory to prostacyclins' is defined as
- Worsening of ulcer(s) within 1 month after prostacyclins iv
- No improvement of ulcer(s) after 2 months after prostacyclins iv, as judged by the referring physician
- Recurrence of exactly the same ulcer(s) (same location) within 3 months after prostacyclins iv
- Written informed consent
Exclusion Criteria:
- Ulcer with underlying calcinosis (ruled out by X-ray prior to screening/inclusion)
- History of neoplasm or malignancy in the past 10 years
- Pregnancy or unwillingness to use adequate contraception during study
- Serious known concomitant disease with life expectancy <1 year
- Uncontrolled hypertension
- Uncontrolled acute or chronic infection with systemic symptoms (e.g. fever)
- Follow-up impossible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MSC injections
Intramuscular injection of mesenchymal stromal cells (50 million allogeneic MSCs in 0.9% NaCl and 10% human serum albumin).
|
8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side.
Blinded syringes will be used.
Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
|
Placebo Comparator: Placebo injections
Intramuscular injection of placebo (NaCl 0.9% + 10% human serum albumin)
|
8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side.
Blinded syringes will be used.
Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Toxicity of the treatment
Time Frame: 12 weeks after MSC administration
|
Toxicity of the treatment is defined as 1.
Local toxicity, including signs of local inflammation (swelling, warmth, impairment of function), worsening of ulcers or new ulcers or hematomas after MSC administration 2. Other adverse events, graded according to the Common Terminology Criteria for Adverse Events version 4.0, expressed as maximum grade toxicity per organ system.
|
12 weeks after MSC administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serious adverse events
Time Frame: 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Any treatment-related serious adverse events (SAE) defined as events leading to hospitalization, death, or persistent or significant disability.
To establish the presence or absence of a causal relationship, the World Health Organisation guidelines for pharmacovigilance will be followed.
|
48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Change in perceived pain based on the Numerical Rating Scale
Time Frame: 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Change in pain as assessed using the Numerical Rating Scale,
|
48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Change in perceived pain based on the digital ulcer visual analogue scale (part of the S-HAQ)
Time Frame: 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Change in pain as assessed using the digital ulcer visual analogue scale (part of the S-HAQ).
|
48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Change in perceived pain based on the pain VAS ( part of the S-HAQ)
Time Frame: 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Change in pain as assessed using the pain VAS (S-HAQ), use of analgesics.
|
48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Change in perceived pain based on the use of analgesics.
Time Frame: 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Change in pain as assessed by analyzing the use of analgesics.
|
48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Quality of life - SF-36
Time Frame: 12, 24 and 52 weeks after MSC administration
|
SF-36 questionnaire.
|
12, 24 and 52 weeks after MSC administration
|
Quality of life - Euroqol
Time Frame: 12, 24 and 52 weeks after MSC administration
|
EuroQol questionnaire
|
12, 24 and 52 weeks after MSC administration
|
Disability
Time Frame: 12, 24 and 52 weeks after MSC administration
|
Assessed with the HAQ-DI questionnaire.
|
12, 24 and 52 weeks after MSC administration
|
Hand function
Time Frame: 12, 24 and 52 weeks after MSC administration
|
Cochin Hand Function Score
|
12, 24 and 52 weeks after MSC administration
|
Number (and change in number) of digital ulcers
Time Frame: 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
|
Healing of digital ulcers
Time Frame: 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Healing of ulcers is defined as complete epithelialization, regardless of residual pain.
This will be established using sequential pictures in addition to the clinical examination.
|
48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Ulcer size
Time Frame: 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Using sequential pictures, ulcer area and circumference will be measured.
|
48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Time to healing of digital ulcers
Time Frame: 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
|
Need to alter medication regime
Time Frame: 48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
The need to alter the medication regime as determined by the patient's attending rheumatologist.
|
48 hours, 2, 4, 8, 12, 24 weeks and 52 weeks after MSC administration
|
Modified Rodnan Skin Score
Time Frame: 12, 24 and 52 weeks after MSC administration
|
12, 24 and 52 weeks after MSC administration
|
|
Severity of Raynaud's symptoms
Time Frame: 12 , 24 and 52 weeks after MSC administration
|
Raynaud Condition Score
|
12 , 24 and 52 weeks after MSC administration
|
Changes in capillary morphology and architecture
Time Frame: 2, 12, 24 weeks and 52 weeks after MSC administration
|
as visualized with video-assisted nailfold capillaroscopy by a trained investigator.
The images will be scored by a certified rheumatologist and a trained investigator.
|
2, 12, 24 weeks and 52 weeks after MSC administration
|
Changes in laboratory parameters
Time Frame: 48 hours, 2, 4, 8, 12 weeks after MSC administration
|
A range of haematological and chemical parameters will be measured for safety assessment.
Additionally, serum, plasma and peripheral blood mononuclear cells will be collected and stored for analysis at a later time point.
Samples will be analysed and used to assess markers for endothelial activation and injury, proangiogenic factors, inflammation and oxidative stress.
The presence of HLA-antibodies will be determined as well.
|
48 hours, 2, 4, 8, 12 weeks after MSC administration
|
Changes in circulating cell populations
Time Frame: 48 hours, 2, 4, 8, 12 weeks after MSC administration
|
Circulating cell populations will be studied by immunofluorescence labelling and analysis using fluorescence assisted cell sorting (FACS Canto machine).
|
48 hours, 2, 4, 8, 12 weeks after MSC administration
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marianne Verhaar, MD, PhD, UMC Utrecht
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MANUS
- 2015-000168-32 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Sclerosis
-
AmgenEnrolling by invitationDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicGermany, Spain, Korea, Republic of, Japan, Mexico, Argentina, Greece, United States, Austria, France, Israel, Poland, United Kingdom
-
AmgenRecruitingDiffuse Cutaneous Systemic Sclerosis | Sclerosis, SystemicUnited States, Korea, Republic of, Germany, Spain, Italy, Israel, Japan, Serbia, Argentina, Greece, Mexico, Poland, Chile, Austria, France, Portugal, Romania, Switzerland, United Kingdom
-
Michael M. PhamTerminatedSystemic Sclerosis | Scleroderma, Systemic | Scleroderma, Diffuse | Diffuse Cutaneous Systemic Sclerosis | Interstitial Lung Disease | Scleroderma | Systemic Sclerosis, Diffuse | Diffuse Systemic Sclerosis | Pulmonary Fibrosis Interstitial | Diffuse Scleroderma | Diffuse Cutaneous Scleroderma | Progressive Systemic... and other conditionsUnited States
-
University of ManchesterCompletedEarly Diffuse Cutaneous Systemic Sclerosis
-
Fred Hutchinson Cancer CenterNational Institute of Allergy and Infectious Diseases (NIAID)CompletedSystemic Scleroderma | Severe Systemic SclerosisUnited States
-
Kyverna TherapeuticsNot yet recruitingSystemic Sclerosis | Systemic Sclerosis - Diffuse Cutaneous | Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
-
Kadmon, a Sanofi CompanyTerminatedDiffuse Cutaneous Systemic Sclerosis | System; SclerosisUnited States
-
Boston UniversityCompleted
-
Federal University of São PauloUnknown
-
Lawson Health Research InstituteMallinckrodtNot yet recruitingDiffuse Cutaneous Systemic SclerosisCanada
Clinical Trials on Mesenchymal stromal cells
-
Leiden University Medical CenterCompletedRejection | Graft LossNetherlands
-
Postgraduate Institute of Medical Education and...UnknownRenal Transplant RejectionIndia
-
Guangzhou General Hospital of Guangzhou Military...First Affiliated Hospital, Sun Yat-Sen University; Guangzhou First People's... and other collaboratorsUnknownSevere Aplastic AnemiaChina
-
Mario Negri Institute for Pharmacological ResearchA.O. Ospedale Papa Giovanni XXIIITerminated
-
Karolinska InstitutetRegion StockholmTerminatedGraft-Versus-Host DiseaseSweden
-
Monia LoriniMario Negri Institute for Pharmacological ResearchUnknown
-
University of LiegeCentre Hospitalier Universitaire de LiegeRecruiting
-
Karolinska University HospitalKarolinska InstitutetUnknownAcute Respiratory Distress Syndrome, AdultSweden
-
Ettore Biagi, MDUnknownGraft vs Host DiseaseItaly
-
ShiCang YuXinqiao Hospital of ChongqingNot yet recruiting